Experimental drug HDP-101 targets Hard-to-Treat myeloma
NCT ID NCT04879043
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests an experimental drug, HDP-101, in people with multiple myeloma or related plasma cell disorders. The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments, including stem cell transplant or are not eligible for one.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HDP-101, an experimental drug given as an infusion
- What this could lead to
- If successful, HDP-101 could offer a new treatment option for patients with multiple myeloma who have exhausted other therapies.
- What could go wrong
- This is an early, first-in-human trial with a small number of participants, so safety and effectiveness are not yet proven. There may be unforeseen side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AIDPORT Sp. zo.o.
RECRUITINGSkórzewo, 60-185, Poland
-
Arensia Clinics SRL
RECRUITINGBucharest, Romania
-
Asklepios Klinik Altona, Haematologie und internistische Onkologie
WITHDRAWNHamburg, 22763, Germany
-
Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie
WITHDRAWNBerlin, 12203, Germany
-
Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III
WITHDRAWNChemnitz, 09116, Germany
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
MICS Centrum Medyczne Torun
RECRUITINGTorun, 87-100, Poland
-
Mount Sinai, The Tisch Cancer Instutute
RECRUITINGNew York, New York, 10029, United States
-
National Institute of Oncology, Department of Oncological Internal Medicine
WITHDRAWNBudapest, 1122, Hungary
-
Nebraska Cancer Institute
NOT_YET_RECRUITINGOmaha, Nebraska, 68130, United States
-
Norton Healthcare, Inc.
NOT_YET_RECRUITINGLouisville, Kentucky, 40202, United States
-
Oncology Institute Prof. Dr. Ion Chiricuta I.O.C.N.
NOT_YET_RECRUITINGCluj-Napoca, Romania
-
Pratia Onkologia Katowice
RECRUITINGKatowice, 40-568, Poland
-
Pratia Onkologia Kraków
RECRUITINGKrakow, 40-519, Poland
-
Pécsi Tudományegyetem Klinikai Központ
NOT_YET_RECRUITINGPécs, 7624, Hungary
-
Semmelweis University, Belgyogyaszati es Onkologiai Klinika
RECRUITINGBudapest, 1083, Hungary
-
Szpital Wojewodzki w Opolu
WITHDRAWNOpole, 45-061, Poland
-
UKSH Campus Lübeck Klinik für Hämatologie und Onkologie
ACTIVE_NOT_RECRUITINGLübeck, 23538, Germany
-
Universitätsklinikum Heidelberg
ACTIVE_NOT_RECRUITINGHeidelberg, 69120, Germany
-
Universitätsklinikum Köln
WITHDRAWNCologne, 50937, Germany
-
Universitätsklinikum Mainz
WITHDRAWNMainz, 55131, Germany
-
Universitätsklinikum Schleswig-Holstein
WITHDRAWNKiel, 24105, Germany
-
Winship Cancer Institute of Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
-
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
WITHDRAWNLodz, 93-513, Poland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a cancer drug reboot the immune system after a stem cell transplant?
- A One-Shot gene therapy could take on incurable blood cancer
- New PET tracer could sharpen diagnosis of blood cancers
- Web tool aims to empower rare cancer patients in genomic choices
- Diabetes drug metformin could boost myeloma treatment